Developing Therapies that Change People's Lives

CLEAR-III Safety Reporting Course

 

CLEAR-III Safety Reporting Course

 

 

{slide=Course Information|closed|noscroll}

Course Summary

Adverse event reporting is a critically-important responsibility of study coordinators and investigators. This course discusses Adverse Events (AEs), Serious Adverse Events (SAEs) and Medical Events of Interest (MEOI's) and explains how they should be documented in the case report forms for the CLEAR III study. Additional topics covered included intensity grading, causality and the functions of the safety team lead by Nichol McBee.

Time required: 1 hour.

Target Audience

Study coordinators, investigators, and site staff on the CLEAR-III study.

Learning Objectives

Learn what to report and how to record it in the case forms.

{/slides}

 

 This course is currently available here as a video viewable on Emissary's website, or as a downloadable PowerPoint below, while it is being transcribed and updated for this website.

 

Name File size    
CLEAR III Safety Reporting Course - PowerPoint 80 KB

 

You are not allowed to access the quiz.

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368

Our Latest Clinical Trials

  • All
  • Active
  • Complete
  • Epilepsy
  • Stroke
  • Default
  • Title
  • Date
  • Random
  • CLEAR-III is an international 500-patient randomized clinical trial evaluating thrombolysis vs. medical management alone in the treatment of intraventricular hemorrhage. With 75 hospitals participating, enrollment is expected to complete in late 2014.
    Read More
    • Active
    • Stroke
  • MISTIE-III is a 500-patient, international multicenter clinical trial launched in 2013 to confirm the safety and long-term efficacy of thrombolysis in the treatment of intracerebral hemorrhage (ICH). The 5-year trial is funded by NINDS and launched in 2013. Up to 100 of the top stroke centers across the world are expected to participate.
    Read More
    • Active
    • Stroke
  • EQUIGEN is composed of two bioequivalency trials. The EQUIGEN Chronic Dose trial is comparing two disparate generics of lamotrigine. The EQUIGEN Single Dose trial is comparing brand lamotrigine with two disparate generics of lamotrigine for patients with epilepsy. BIOS serves as the Coordinating Center for both trials.
    Read More
    • Active
    • Epilepsy
  • ICES was the third tier in the MISTIE phase-II clinical trial. ICES evaluated minimally-invasive endoscopic removal of the intracerebral hematoma as a faster alternative to catheter-delivered intermittent thrombolytic therapy. The last patient completed in 2013. Publication of final results is forthcoming. Meanwhile, plans are underway for the next phase of thise program.
    Read More
    • Complete
    • Stroke
  • SMARTS is a study conducted by Dr. John Krakauer exploring how the brain changes over the first year following a stroke. We are using several non-invasive techniques, including MRI, transcranial magnetic stimulation and measures of arm movement to learn more about how individuals recover from stroke.
    Read More
    • Active
    • Stroke
load more hold SHIFT key to load all load all